Cagrilintide is a synthetic, lipidated amylin-analog peptide supplied as a characterized reference material for receptor pharmacology, peptide chemistry, and comparative amylin/incretin research. This page explains the structural and assay context without turning preclinical literature into human-use claims.
Molecular architecture
Cagrilintide is described as a 37-residue amylin analog with sequence substitutions and an N-terminal fatty-diacid modification connected through a linker. The catalog record reports an approximate molecular formula of C₁₉₄H₃₁₂N₅₄O₅₉S₂ and a molecular weight near 4409 g/mol. Because lipidated peptides can be reported with different conventions, the lot COA remains the controlling document for identity and purity.
Receptor research
Amylin analogs are studied across amylin-receptor complexes that combine calcitonin-receptor or related receptor components. Cagrilintide is therefore relevant to binding, receptor activation, second-messenger, internalization, and comparative ligand assays. Researchers should specify receptor composition and expression system: a result from one receptor complex cannot automatically be transferred to another.
Comparative studies
Cagrilintide can serve as a comparator in experiments that examine amylin signaling alongside GLP-1 or other incretin pathways. Useful controls include native peptide comparators, receptor-negative cells, vehicle controls, and orthogonal analytical measurements. Interpretation should stay close to the data and identify whether a finding concerns binding, signaling potency, stability, or a downstream model phenotype.
Handling and evidence limits
Use the supplier’s SDS, lot-specific COA, and institutional procedures for storage, reconstitution, contamination control, and disposal. Published cell or animal findings do not establish human or veterinary safety or efficacy. Helix supplies this material for laboratory research only; it is not for human or veterinary use, diagnostic use, or therapeutic use.
Every Cagrilintide order includes a sealed, lot-controlled vial, the completed lot documentation, and a handling & storage card. Product-specific handling follows the supplied documentation and institutional SOPs.
Evidence limits and research safety
Research findings can differ by model, assay, purity, formulation, and study design. Published cell, biochemical, and pre-clinical observations do not establish human or veterinary safety, efficacy, dosing, or suitability. Researchers should review the applicable SDS, institutional safety procedures, waste requirements, and lot-specific documentation before handling any reference material.
Related research
Tirzepatide · Retatrutide · Semaglutide
Credible sources
- PubChem — Cagrilintide
- PubMed — cagrilintide amylin-receptor literature
- PubMed — amylin receptor pharmacology